Claritas Pharmaceuticals Inc V.CLAS.H

Primary Symbol: CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

GREY:CLAZF - Post by User

Claritas Pharmaceuticals Inc > One Year since the Engagement of Echelon

<< Previous

Bullboard Posts

Next >>

Comment by Chritterson Apr 30, 2020 12:59pm

182 Views

Post# 30972100

RE:One Year since the Engagement of Echelon

It does say this regarding it though!! The Company does not intend to discuss developments with respect to the review process unless a transaction is approved, or further disclosure becomes appropriate.

Probably nothing became of it.

<< Previous

Bullboard Posts

Next >>

The top 5 Canadian small-cap AI stocks